Gregory S. Rush Sells 35,503 Shares of INC Research Holdings Inc. (INCR) Stock
INC Research Holdings Inc. (NASDAQ:INCR) VP Gregory S. Rush sold 35,503 shares of the stock in a transaction on Friday, September 30th. The shares were sold at an average price of $44.70, for a total transaction of $1,586,984.10. Following the sale, the vice president now directly owns 82,712 shares of the company’s stock, valued at approximately $3,697,226.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of INC Research Holdings Inc. (NASDAQ:INCR) opened at 46.42 on Thursday. The stock has a market capitalization of $2.54 billion, a PE ratio of 22.89 and a beta of 1.80. The stock has a 50 day moving average of $44.19 and a 200 day moving average of $43.52. INC Research Holdings Inc. has a 52-week low of $34.19 and a 52-week high of $57.11.
INC Research Holdings (NASDAQ:INCR) last issued its earnings results on Thursday, July 28th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.58 by $0.03. The firm earned $258.80 million during the quarter, compared to analyst estimates of $252.39 million. INC Research Holdings had a net margin of 7.43% and a return on equity of 46.76%. The business’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.47 earnings per share. Analysts forecast that INC Research Holdings Inc. will post $2.47 earnings per share for the current year.
Several equities research analysts have weighed in on the stock. Goldman Sachs Group Inc. increased their price target on shares of INC Research Holdings from $60.00 to $62.00 and gave the company a “buy” rating in a research report on Friday, August 12th. Zacks Investment Research raised shares of INC Research Holdings from a “hold” rating to a “strong-buy” rating and set a $51.00 price target for the company in a research report on Friday, August 19th. Jefferies Group dropped their price target on shares of INC Research Holdings from $56.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, August 17th. Finally, Credit Suisse Group AG assumed coverage on shares of INC Research Holdings in a research report on Monday, June 20th. They set an “outperform” rating and a $51.00 price target for the company. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $55.00.
Several hedge funds have recently modified their holdings of the stock. Acrospire Investment Management LLC bought a new stake in shares of INC Research Holdings during the first quarter worth about $117,000. Rational Advisors LLC bought a new stake in shares of INC Research Holdings during the second quarter worth about $109,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of INC Research Holdings by 302.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,052 shares of the company’s stock worth $116,000 after buying an additional 2,294 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of INC Research Holdings by 121.8% in the third quarter. BNP Paribas Arbitrage SA now owns 3,606 shares of the company’s stock worth $161,000 after buying an additional 1,980 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of INC Research Holdings by 4.6% in the second quarter. BlackRock Inc. now owns 4,810 shares of the company’s stock worth $183,000 after buying an additional 213 shares in the last quarter. 91.27% of the stock is owned by hedge funds and other institutional investors.
INC Research Holdings Company Profile
INC Research Holdings, Inc is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.